Phase 7 · Scale · Sustain · Expand · From Traction to Legacy
Healthcare & Life Sciences Growth Programme
Healthcare and life sciences businesses operate under regulatory constraints that most sectors do not face — and grow through evidence, trust, and the clinical validation that makes the difference between a product the market adopts and one it ignores.
The Healthcare and Life Sciences Growth Programme is the strategic and commercial support for healthcare providers, medical device companies, pharmaceutical businesses, digital health innovators, and life sciences organisations — navigating the regulatory environment, the evidence requirements, and the market access challenges that determine whether commercially sound healthcare innovations reach the patients and practitioners who need them.
The Pain We Solve
You may recognise yourself in one of these.
Three audience scenarios · because the same service produces a different transformation depending on where you are in the business journey.
Scenario 1
The healthcare innovator with a clinically effective product that cannot achieve market adoption because it lacks the evidence base and the clinical champion network that commissioning bodies require
The product works. The clinical evidence is compelling to the team that developed it. And the NHS commissioners, the CCGs, and the clinical procurement bodies that would adopt it at scale have not done so — because the evidence is not in the form they require, the clinical champions who would advocate for it have not been recruited, and the commissioning pathway has not been navigated.
Scenario 2
The digital health business whose product has been developed without adequate engagement with the clinical end users and is finding that adoption is lower than expected
The digital health product is technically sound and clinically appropriate. The clinical users who were supposed to adopt it are not using it — because the workflow integration is poor, the training was inadequate, or the product was designed without the clinical input that would have made it fit the way clinical teams actually work.
Scenario 3
The life sciences business with a strong domestic market position that wants to expand internationally but is uncertain how to navigate the regulatory requirements and the market access challenges in target markets
The domestic commercial performance is strong. The international opportunity is clear. And the regulatory approval pathways, the market access requirements, and the local clinical evidence standards in the target markets are sufficiently different from the UK that the domestic commercial model cannot be applied directly.
The Impact It Creates
The Moment You Will Feel the Difference.
Clinical evidence positioned for commissioning bodies in the format and the framing they require
Clinical champion network developed — the practitioners who advocate for adoption
Digital health product adoption improved through clinical workflow integration
International regulatory and market access pathway designed for target markets
What You Receive
The Specific Deliverables.
Tangible outputs · documented, dated, and yours to keep.
- Healthcare growth strategy
- Evidence positioning and health economics framework
- Commissioning pathway navigation strategy
- Clinical champion identification and engagement programme
- Digital health adoption programme
- International regulatory and market access strategy
The Outcome
Where You Will Be on the Other Side.
The healthcare or life sciences business achieves the market adoption its clinical evidence justifies — through a commercial strategy that navigates the regulatory environment, builds the clinical advocacy network, and positions the evidence in the form that commissioners and practitioners require.
Primary Focus
Growing the healthcare or life sciences business through evidence positioning, clinical champion development, and regulatory-aware market access strategy.
KPI Measurement
- Commissioning body adoption rate
- Clinical champion network size and advocacy activity
- Digital health product active usage rate
- Revenue from internationally approved markets
- Health economics evidence strength score
Investment & ROI
Pricing Engineered Around the Value You Create.
Every engagement is sized against the value we believe we can create with you · the fee is always a fraction of the outcome. Four tiers · so the investment matches your stage of business.
Tier 1
Foundations
£5,000 – £15,000
Right for
Pre-startup, startup, and micro-business founders ready to build on evidence rather than instinct.
Typical Value Created
£250K+ in scale-readiness, governance maturity, and expansion clarity
Engagement
4 – 8 weeks
Target Return
5 – 10× ROI
within 12 – 18 months
Tier 2
Acceleration
£15,000 – £50,000
Right for
Growing SMEs and established small businesses ready to scale a working model into the next revenue band.
Typical Value Created
£1M – £10M in expansion velocity, new-market revenue, and capital readiness
Engagement
8 – 16 weeks
Target Return
5 – 10× ROI
within 12 – 18 months
Tier 3
Transformation
£50,000 – £250,000
Right for
Medium enterprises and scale-stage businesses ready to commit to a multi-quarter, organisation-wide shift.
Typical Value Created
£5M – £50M in scale outcomes, M&A optionality, and leadership-capability uplift
Engagement
3 – 9 months
Target Return
5 – 10× ROI
within 12 – 18 months
Tier 4
Enterprise
£250,000 – £2M+
Right for
Large enterprises, global operators, and complex organisations ready for a multi-year strategic partnership.
Typical Value Created
£25M+ in enterprise value created, capital events optimised, and legacy structures built
Engagement
12 months and onward
Target Return
5 – 10× ROI
within 12 – 18 months
Why We Price This Way
Every engagement is sized around the value we believe we can create with you. The fee is always a fraction of the outcome · typically 10 – 20% of the expected first-year return.
This is how we make sure pricing aligns with results. The conversation is never “what does this cost?” · it is always “what is this worth to your business?” We answer that together in the first call, transparently, and decide the right tier from there.
If we cannot articulate a credible 5–10× return for your specific situation, we will tell you in the first call. That honesty is part of why our clients trust us with the work that matters most.
Why This Conversation Matters
“Great healthcare products that do not reach patients are not just commercial failures — they are clinical failures. The commercial strategy that closes the gap between a product that works and the patients who benefit from it is one of the most important things a healthcare business can invest in. We design that strategy.”
A 90-minute structured strategy session · produces a usable roadmap whether you engage further or not.
More in Phase 7